1395443-04-5 Usage
Description
3-Iodo-1,4-dimethyl-1H-pyrazole is a pyrazole derivative with the molecular formula C6H8IN2. It features an iodo substituent at the 3-position and methyl groups at the 1 and 4 positions, making it a versatile building block in organic synthesis.
Uses
Used in Pharmaceutical Industry:
3-Iodo-1,4-dimethyl-1H-pyrazole is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique structural features and reactivity, contributing to the development of new drugs.
Used in Agrochemical Industry:
3-Iodo-1,4-dimethyl-1H-pyrazole also serves as a building block in the preparation of agrochemicals, where its properties can be leveraged to create effective products for agricultural applications.
Used in Medicinal Research:
3-Iodo-1,4-dimethyl-1H-pyrazole is utilized in medicinal research for studying its potential biological activities, which may lead to the discovery of new therapeutic agents or contribute to a better understanding of biological processes.
Used in Organic Synthesis:
As a versatile intermediate, 3-Iodo-1,4-dimethyl-1H-pyrazole is widely used in organic synthesis for the production of a diverse range of chemical compounds, showcasing its importance in the field of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1395443-04-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,5,4,4 and 3 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1395443-04:
(9*1)+(8*3)+(7*9)+(6*5)+(5*4)+(4*4)+(3*3)+(2*0)+(1*4)=175
175 % 10 = 5
So 1395443-04-5 is a valid CAS Registry Number.
1395443-04-5Relevant articles and documents
NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS
-
Paragraph 575, (2021/12/28)
The present disclosure provides compounds having Formula (I): (I) and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R6, R6', R7, and R7' are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.
COMPOUND, COMPOSITIONS, AND METHODS
-
Page/Page column 206, (2017/08/01)
Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
